Summary:
The purpose of this study is to evaluate the safety and tolerability of treatment with atogepant 60 mg daily for the prevention of migraine headaches in participants with episodic migraine headaches. The study will consist of a 4-week screening and baseline period, a 52-week treatment period, and a safety follow-up period of an additional 4 weeks, for a total duration of 60 weeks.
Qualified Participants Must:
• Must be 18 to 80 years of age
•
Must have at least 1 year history of Migraines
Qualified Participants May Receive:
Study related care, investigational product at no cost and may receive up to $800 for time and travel.